The interview explores the treatment algorithm from localized to metastatic prostate cancer, focusing on the rationale for prescribing various androgen deprivation therapies and ARPIs. It also discusses challenges related to NICE reimbursement, the limited availability of certain therapies in the UK, and the uptake of radiotherapy options.

This interview was conducted on Feb 11, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.